Analyst Consensus ?
ConsensusHold13 ratings
Bullish538.5%
Neutral753.8%
Bearish17.7%
Viatris Inc. · VTRS · FY2024 Q3 · Calendar Q4 2024
Viatris Maintains Guidance as Pipeline and Deleveraging Advance
Viatris's latest analysis supports a steady, execution-led outlook: base-business growth and pipeline progress are paired with substantial deleveraging, while the main debate is how quickly new products convert into durable revenue.
Reported Before market openNASDAQHealthcare
$21.01B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.75
Consensus $0.68
EPS surprise
+10.3%
Reported versus consensus
Reported revenue
$3.74B
Consensus $3.62B
Revenue surprise
+3.1%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+13.5%
Event window
SPY move
+0.8%
Same window
Abnormal move
+12.7%
Stock minus SPY
Volume
4.3×
Versus trailing sessions
Subsequent drift
-3.5%
Up to 20 sessions
VTRSSPY benchmark
Ask FN2 about VTRS FY2024 Q3
Transcript, numbers and history already loaded
Why did VTRS rise 13.5% after beating EPS estimates in FY2024 Q3?What changed in VTRS's guidance and outlook in FY2024 Q3?Give me the bull and bear case for VTRS after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the current analysis shows guidance maintained rather than raised, debt repayment of $1.9 billion with net debt below $15 billion, and a more explicit capital-allocation link to reaching the leverage target. New developments include the Lexicon sotagliflozin licensing agreement and positive EFFEXOR top-line results in Japan.
Guidance delta
Management maintained FY2024 guidance while targeting annual new-product revenue of $450 million to $550 million going forward.
Key takeaways
- Management analysis indicates Q3 operational revenue grew 3% year over year, with strong free cash flow generation.
- Debt repayment of $1.9 billion brought net debt below $15 billion; management is targeting roughly 3x gross leverage by year-end.
- The pipeline advanced through EFFEXOR in Japan, sotagliflozin licensing, and continued work on selatogrel and cenerimod.
- Capital allocation is expected to emphasize share repurchases and disciplined business development once the leverage target is achieved.
Management priorities
- Reduce leverage toward roughly 3x gross leverage by year-end.
- Advance selatogrel, cenerimod, and ophthalmology programs.
- Develop and launch near-market products, including sotagliflozin in emerging markets.
- Balance future share repurchases with disciplined business development.
Follow VTRS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$18.29Current
$12Low
$18.64Average
$26High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Neutral | Neutral | Maintain | Oct 26, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Oct 21, 2026 |
| UBS | Buy | Buy | Maintain | Oct 5, 2026 |
| Argus Research | Buy | Buy | Maintain | Sep 8, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 19, 2026 |
| Truist Securities | Buy | Buy | Maintain | May 8, 2026 |
| Jefferies | Buy | Buy | Maintain | Mar 7, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Feb 28, 2025 |
| BMO Capital | Market Perform | Outperform | Downgrade | Feb 17, 2023 |
| Goldman Sachs | Neutral | Neutral | Maintain | May 12, 2022 |
| Citigroup | Neutral | Neutral | Maintain | Mar 10, 2022 |
| Raymond James | Market Perform | Outperform | Downgrade | Mar 1, 2022 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Mar 10, 2021 |
Named analyst price targets
Upside is calculated against the persisted current price $18.29. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | David Amsellem | $14 | $18 | -23.5% | Oct 26, 2026 |
| UBS | Ashwani Verma | $26 | $17.6 | +42.2% | Oct 5, 2026 |
| Oppenheimer | Analyst unavailable | $25 | $17.18 | +36.7% | Sep 23, 2026 |
| Leerink Partners | Analyst unavailable | $20 | $16.61 | +9.3% | Sep 9, 2026 |
| Argus Research | Analyst unavailable | $20 | $16.75 | +9.3% | Sep 8, 2026 |
| Barclays | Glen Santangelo | $22 | $16.5 | +20.3% | May 19, 2026 |
| Truist Financial | Analyst unavailable | $20 | $16.94 | +9.3% | May 8, 2026 |
| UBS | Ashwani Verma | $18 | $14.58 | -1.6% | Feb 9, 2026 |
| Piper Sandler | Analyst unavailable | $12 | $13.12 | -34.4% | Jan 28, 2026 |
| Argus Research | Analyst unavailable | $15 | $12.84 | -18.0% | Jan 16, 2026 |
| Truist Financial | Les Sulewski | $16 | $12.4 | -12.5% | Jan 7, 2026 |
| Truist Financial | Analyst unavailable | $15 | $9.93 | -18.0% | Oct 15, 2025 |
| Jefferies | Glen Santangelo | $15 | $11.77 | -18.0% | Jul 19, 2024 |
| Piper Sandler | David Amsellem | $13 | $11.83 | -28.9% | Mar 28, 2024 |
| Piper Sandler | David Amsellem | $10 | $9.84 | -45.3% | Jun 26, 2023 |
| Barclays | Analyst unavailable | $15 | $12.16 | -18.0% | Feb 1, 2023 |
| UBS | Ashwani Verma | $12 | $10.83 | -34.4% | Nov 9, 2022 |
| UBS | Ashwani Verma | $9 | $10.77 | -50.8% | Jun 13, 2022 |
Track every rating change on VTRS the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationViatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors.…
Historical context
All VTRS earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
Latest beats and misses
Who reports nextBeat on EPS
- CDNSFY2026 Q3 · October 26, 2026+2.9% EPS+1.8% move
- BAHFY2027 Q2 · October 23, 2026+18.9% EPS-0.3% move
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the VTRS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-27T03:00:43.347777+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-27T03:00:43.344904+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-27. For educational purposes only; not investment advice.